



Bibliographie

Dose de rappel

1. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel [Internet]. 2021 Aug [cited 2021 Sep 15] p. 2021.08.24.21262423. Available from: <https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1>

Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Six -Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study [Internet]. Rochester, NY: Social Science Research Network; 2021 Aug [cited 2021 Sep 15]. Report No.: ID 3909743. Available from: <https://papers.ssrn.com/abstract=3909743>

Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021 Oct 6;

Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID19 in the UK [Internet]. Epidemiology; 2021 Sep [cited 2021 Oct 25]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.09.15.21263583>

Nordström P, Ballin M, Nordström A. Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study [Internet]. Rochester, NY: Social Science Research Network; 2021 Oct [cited 2021 Nov 17]. Report No.: ID 3949410. Available from: <https://papers.ssrn.com/abstract=3949410>

Canaday DH, Carias L, Oyebanji OA, Keresztesy D, Wilk D, Payne M, et al. Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents. medRxiv. 2021 Mar 22;2021.03.19.21253920.

Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 Sep 17;373(6561):1372–7.

Aldridge RW, Yavlinsky A, Nguyen V, Eyre MT, Shrotri M, Navaratnam AMD, et al. Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort [Internet]. 2021 Nov [cited 2021 Nov 17] p. 2021.11.05.21265968. Available from: <https://www.medrxiv.org/content/10.1101/2021.11.05.21265968v1>

2. [Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 \(Delta\) Variant Predominance – Eight U.S. Locations, December 2020–August 2021 | MMWR \(cdc.gov\)](#)

3. Catteau L., van Loenhout J., Stouten V., Billuart M., Hubin P., Haarhuis F., Wyndham Thomas C. Couverture vaccinale et impact épidémiologique de la campagne de vaccination COVID-19 en Belgique. Données jusqu'au 31 octobre 2021 inclus. Bruxelles, Belgique: Sciensano ; 2021. Numéro de dépôt légal : D/2021/14.440/79 [Thematic report : \(sciensano.be\)](#)

4. Superior Health Council: Booster vaccination against COVID-19 for the general population. Brussels: SHC; 2021. Report 9683 [20211216_shc-9683_booster_with_annex_vweb.pdf \(belgium.be\)](#)

5. [Protection against Covid-19 by BNT162b2 Booster across Age Groups | NEJM](#)

6. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1040076/Technical_Briefing_31.pdf

Séance d'info – Vaccination Covid-19 et 3^{ème} dose. Cliniques Universitaires Saint-Luc, Pr. Leila Belkhir. <https://livestream.com/cavstream/events/9482619/videos/227654553>

BNT162b2 Vaccine booster and mortality due to Covid-19. Ronen Arbel et collaborateurs. (8 décembre 2021). The New England Journal of Medicine. <https://www.nejm.org/doi/full/10.1056/NEJMoa2115624>

Un document provenant du conseil supérieur de la santé :

Superior Health Council: Booster vaccination against COVID-19 for the general population. Brussels: SHC; 2021. Report 9683.

https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20211216_shc-9683_booster_with_annex_vweb.pdf

Un document provenant du KCE :

KCE : Rapid review of the evidence on a covid-19 booster dose after a primary vaccination schedule – Report for the task force vaccination; 2021. D/2021/10.273/26.

https://kce.fgov.be/sites/default/files/atoms/files/Third%20Covid-19%20vaccination_Report_DUTCH.pdf

Barda et al., Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel:

an observational study. *The Lancet Journal*. 2021; 398: 2093-100.

<https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2902249-2>